GlassScriptPhysician profile
Dorothy E Agbafe-Mosley
NPI 1881898187
$6,995.23
in general payments reported to CMS, 2019-2025
45 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $434 · 2021: $862 · 2022: $890 · 2023: $985 · 2024: $1,918 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.75 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $842.59 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $632.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $612.25 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $508.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $377.30 | 2020-2025 | Nexletol |
| Pfizer INC. | $317.56 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $312.75 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.82 | 2019-2023 | Relistor |
| Paratek Pharmaceuticals, INC. | $222.33 | 2023-2025 | Nuzyra |
| Daiichi Sankyo INC. | $217.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $192.44 | 2022-2024 | Rexulti |
| Exact Sciences Corporation | $158.44 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $141.76 | 2024-2025 | Epclusa |
| Axsome Therapeutics, INC. | $137.96 | 2022-2025 | Auvelity, Symbravo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Agbafe-Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.